GT201100308A - Derivados de 1-(piperidin-4-il)-pirazol como moduladores de gpr 119 - Google Patents
Derivados de 1-(piperidin-4-il)-pirazol como moduladores de gpr 119Info
- Publication number
- GT201100308A GT201100308A GT201100308A GT201100308A GT201100308A GT 201100308 A GT201100308 A GT 201100308A GT 201100308 A GT201100308 A GT 201100308A GT 201100308 A GT201100308 A GT 201100308A GT 201100308 A GT201100308 A GT 201100308A
- Authority
- GT
- Guatemala
- Prior art keywords
- pirazol
- gpr
- piperidin
- modulators
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRESENTE SOLICITUD DESCRIBE COMPUESTOS DE FÓRMULA I QUE MODULAN LA ACTIVIDAD DEL RECEPTOR ACOPLADO A PROTEÍNA G GPR119 Y SUS USOS EN EL TRATAMIENTO DE ENFERMEDADES LIGADAS A LA MODULACIÓN DEL RECEPTOR ACOPLADO A PROTEÍNA G GPR119.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18435509P | 2009-06-05 | 2009-06-05 | |
US25762109P | 2009-11-03 | 2009-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201100308A true GT201100308A (es) | 2013-11-11 |
Family
ID=42358441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201100308A GT201100308A (es) | 2009-06-05 | 2011-12-01 | Derivados de 1-(piperidin-4-il)-pirazol como moduladores de gpr 119 |
Country Status (33)
Country | Link |
---|---|
US (1) | US20110020460A1 (es) |
EP (1) | EP2438051A1 (es) |
JP (1) | JP2012528847A (es) |
KR (1) | KR20120061063A (es) |
CN (1) | CN102459222B (es) |
AP (1) | AP2799A (es) |
AR (1) | AR076985A1 (es) |
AU (1) | AU2010255422B2 (es) |
BR (1) | BRPI1014636A2 (es) |
CA (1) | CA2764021C (es) |
CL (1) | CL2011003085A1 (es) |
CO (1) | CO6470897A2 (es) |
CR (1) | CR20110623A (es) |
CU (1) | CU20110225A7 (es) |
DO (1) | DOP2011000371A (es) |
EA (1) | EA020106B1 (es) |
EC (1) | ECSP11011493A (es) |
GE (1) | GEP20135907B (es) |
GT (1) | GT201100308A (es) |
HN (1) | HN2011003195A (es) |
IL (1) | IL216772A0 (es) |
MA (1) | MA33334B1 (es) |
MX (1) | MX2011013034A (es) |
NI (1) | NI201100204A (es) |
NZ (1) | NZ596467A (es) |
PE (1) | PE20120399A1 (es) |
SG (1) | SG175995A1 (es) |
SV (1) | SV2011004063A (es) |
TN (1) | TN2012000073A1 (es) |
TW (1) | TWI411611B (es) |
UY (1) | UY32683A (es) |
WO (1) | WO2010140092A1 (es) |
ZA (1) | ZA201108481B (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120046188A (ko) | 2009-06-24 | 2012-05-09 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 신규 화합물, 약제학적 조성물 및 이에 관련된 방법 |
AR077214A1 (es) | 2009-06-24 | 2011-08-10 | Neurocrine Biosciences Inc | Heterociclos nitrogenados y composiciones farmaceuticas que los contienen |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
AU2011228699B2 (en) | 2010-03-19 | 2016-05-19 | Pfizer Inc. | 2,3 dihydro-1H-inden-1-yl- 2,7-diazaspiro [3.5] nonane derivatives and their use as antagonists or inverse agonists of the Ghrelin receptor |
HUE025078T2 (en) | 2010-10-29 | 2016-01-28 | Pfizer | N1 / N2-lactam-acetyl-CoA carboxylase inhibitors |
BR112013011865A2 (pt) * | 2010-11-23 | 2016-08-23 | Pfizer | moduladores de gpr119 |
EA022375B1 (ru) | 2011-04-22 | 2015-12-30 | Пфайзер Инк. | ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ |
WO2012170867A1 (en) | 2011-06-09 | 2012-12-13 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of gpr-119 |
CA2841757A1 (en) | 2011-07-15 | 2013-01-24 | Etzer Darout | Gpr 119 modulators |
KR20140023441A (ko) | 2011-07-22 | 2014-02-26 | 화이자 인코포레이티드 | 퀴놀린일 글루카곤 수용체 조절제 |
WO2013030713A1 (en) | 2011-08-31 | 2013-03-07 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds |
AU2012335220B2 (en) | 2011-11-11 | 2017-06-01 | Pfizer Inc. | 2-thiopyrimidinones |
MD20140103A2 (ro) | 2012-04-06 | 2015-01-31 | Pfizer Inc. | Inhibitori ai diacilglicerol aciltransferazei 2 |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US9309232B2 (en) * | 2012-04-24 | 2016-04-12 | Board Of Trustees Of Northern Illinois University | Synthesis of novel inhibitors of isoprenoid biosynthesis |
CA2872154C (en) | 2012-05-04 | 2016-08-23 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2 |
EP2872127A1 (en) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
CA2882389A1 (en) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
JP2016502978A (ja) | 2012-12-11 | 2016-02-01 | ファイザー・インク | BACE1の阻害剤としてのヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
EP2935282A1 (en) | 2012-12-19 | 2015-10-28 | Pfizer Inc. | CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS |
WO2014125394A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
CA2926568C (en) | 2013-10-09 | 2017-09-05 | Pfizer Inc. | Antagonists of prostaglandin ep3 receptor |
WO2015140658A1 (en) | 2014-03-17 | 2015-09-24 | Pfizer Inc. | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders |
ES2910128T3 (es) | 2014-04-04 | 2022-05-11 | Pfizer | Compuestos de heteroarilo o arilo fusionados con biciclo y su uso como inhibidores de IRAK4 |
MX2016013329A (es) | 2014-04-10 | 2017-01-26 | Pfizer | 2-amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8h )-il-1,3-tiazol-4-ilamidas. |
JP2017119628A (ja) * | 2014-05-09 | 2017-07-06 | 日産化学工業株式会社 | 置換アゾール化合物及び糖尿病治療薬 |
WO2016092413A1 (en) | 2014-12-10 | 2016-06-16 | Pfizer Inc. | Indole and indazole compounds that activate ampk |
JP2017538769A (ja) | 2014-12-22 | 2017-12-28 | ファイザー・インク | プロスタグランジンep3受容体の拮抗薬 |
MX2017011257A (es) | 2015-03-03 | 2018-04-10 | Saniona As | Formulacion de combinacion de tesofensina y betabloqueante. |
MX2017014128A (es) | 2015-05-05 | 2018-03-15 | Pfizer | 2-tiopirimidinonas. |
CA2987179C (en) | 2015-05-29 | 2020-08-25 | Pfizer Inc. | Heterocyclic compounds as inhibitors of vanin-1 enzyme |
CA2989456C (en) | 2015-06-17 | 2022-01-04 | Pfizer Inc. | Tricyclic compounds and their use as phosphodiesterase inhibitors |
WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
AU2016305590A1 (en) | 2015-08-13 | 2018-02-15 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds |
HUE053705T2 (hu) | 2015-08-27 | 2021-07-28 | Pfizer | Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként |
WO2017037567A1 (en) | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Regulators of frataxin |
JP2018531923A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | N−[2−(2−アミノ−6,6−二置換−4,4a,5,6−テトラヒドロピラノ[3,4−d][1,3]チアジン−8a(8H)−イル)−1,3−チアゾール−4−イル]アミド |
EP3353182A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
WO2017051294A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors |
GEP20207147B (en) | 2015-12-29 | 2020-09-10 | Pfizer | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
US10155766B2 (en) | 2016-06-14 | 2018-12-18 | Board Of Trustees Of Northern Illinois University | Pyrazolopyrimidine antibacterial agents |
SG11201811161YA (en) | 2016-07-14 | 2019-01-30 | Pfizer | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
WO2019133445A1 (en) | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles as inhibitors of vanin-1 |
CA3110601C (en) | 2018-08-31 | 2023-09-05 | Pfizer Inc. | Combinations for treatment of nash/nafld and related diseases |
WO2020102575A1 (en) | 2018-11-16 | 2020-05-22 | Inception Ibd, Inc. | Heterocyclic aminothiazoles and uses thereof |
US20220387402A1 (en) | 2019-05-20 | 2022-12-08 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
WO2020261144A1 (en) | 2019-06-28 | 2020-12-30 | Pfizer Inc. | 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases |
TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶2 抑制劑 |
JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
WO2021250541A1 (en) | 2020-06-09 | 2021-12-16 | Pfizer Inc. | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof |
WO2023026180A1 (en) | 2021-08-26 | 2023-03-02 | Pfizer Inc. | Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide |
IL312296A (en) | 2021-12-01 | 2024-06-01 | Pfizer | 3-PHENYL-1-BENZOTHIOPEN-2-CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF BRANCHED ALPHA KETO ACID DEHYDROGENSIS KINASE FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART |
WO2023105387A1 (en) | 2021-12-06 | 2023-06-15 | Pfizer Inc. | Melanocortin 4 receptor antagonists and uses thereof |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024075051A1 (en) | 2022-10-07 | 2024-04-11 | Pfizer Inc. | Hsd17b13 inhibitors and/or degraders |
WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
WO2024118524A1 (en) | 2022-11-28 | 2024-06-06 | Cerevel Therapeutics, Llc | Azaindole compounds and their use as phosphodiesterase inhibitors |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE05440B1 (et) | 2001-02-28 | 2011-08-15 | Merck & Co., Inc. | Atslitud piperidiini derivaadid kui melanokortiin-4 retseptori agonistid, farmatseutiline kompositsioon ning kasutamine ravimi valmistamiseks |
MXPA04008298A (es) | 2002-02-27 | 2004-11-26 | Pfizer Prod Inc | Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico. |
US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
EP2287166A3 (en) * | 2003-07-14 | 2011-06-22 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
AU2004275842B2 (en) | 2003-09-26 | 2010-09-02 | Exelixis Inc. | c-MET modulators and methods of use |
UA84208C2 (en) | 2004-05-25 | 2008-09-25 | Пфайзер Продактс Инк. | Tetraazabenzo(e)azulene derivatives and analogs thereof |
DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
DOP2006000009A (es) * | 2005-01-13 | 2006-08-15 | Arena Pharm Inc | Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
AU2006299091A1 (en) * | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
GB0522846D0 (en) | 2005-11-09 | 2005-12-21 | Peakdale Molecular Ltd | Process |
EP2021014A1 (en) * | 2006-05-26 | 2009-02-11 | Brystol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
US20100144751A1 (en) | 2007-03-28 | 2010-06-10 | Array Biopharma Inc. | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
EP2152707B1 (en) | 2007-05-04 | 2012-06-20 | Bristol-Myers Squibb Company | [6,5]-bicyclic gpr119 g protein-coupled receptor agonists |
AU2008279447A1 (en) * | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
JP2011513233A (ja) | 2008-02-22 | 2011-04-28 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Gpr119活性モジュレーターとしての化合物および組成物 |
BRPI0909469A2 (pt) * | 2008-03-31 | 2015-12-29 | Metabolex Inc | compostos de oximetileno de arila e usos dos mesmos |
US8536176B2 (en) * | 2008-08-01 | 2013-09-17 | Nippon Chemiphar Co., Ltd. | GPR119 agonist |
-
2010
- 2010-05-27 JP JP2012513706A patent/JP2012528847A/ja active Pending
- 2010-05-27 MX MX2011013034A patent/MX2011013034A/es active IP Right Grant
- 2010-05-27 AP AP2011006020A patent/AP2799A/xx active
- 2010-05-27 EP EP10724593A patent/EP2438051A1/en not_active Withdrawn
- 2010-05-27 AU AU2010255422A patent/AU2010255422B2/en not_active Expired - Fee Related
- 2010-05-27 WO PCT/IB2010/052377 patent/WO2010140092A1/en active Application Filing
- 2010-05-27 BR BRPI1014636A patent/BRPI1014636A2/pt not_active IP Right Cessation
- 2010-05-27 CN CN201080024529.7A patent/CN102459222B/zh not_active Expired - Fee Related
- 2010-05-27 KR KR1020117028964A patent/KR20120061063A/ko not_active Application Discontinuation
- 2010-05-27 EA EA201190280A patent/EA020106B1/ru not_active IP Right Cessation
- 2010-05-27 MA MA34412A patent/MA33334B1/fr unknown
- 2010-05-27 PE PE2011002028A patent/PE20120399A1/es not_active Application Discontinuation
- 2010-05-27 SG SG2011082922A patent/SG175995A1/en unknown
- 2010-05-27 NZ NZ596467A patent/NZ596467A/en not_active IP Right Cessation
- 2010-05-27 CA CA2764021A patent/CA2764021C/en not_active Expired - Fee Related
- 2010-05-27 GE GEAP201012490A patent/GEP20135907B/en unknown
- 2010-06-02 TW TW099117782A patent/TWI411611B/zh not_active IP Right Cessation
- 2010-06-03 UY UY0001032683A patent/UY32683A/es unknown
- 2010-06-04 AR ARP100101987A patent/AR076985A1/es not_active Application Discontinuation
- 2010-06-04 US US12/793,938 patent/US20110020460A1/en not_active Abandoned
-
2011
- 2011-11-16 SV SV2011004063A patent/SV2011004063A/es not_active Application Discontinuation
- 2011-11-18 NI NI201100204A patent/NI201100204A/es unknown
- 2011-11-18 ZA ZA2011/08481A patent/ZA201108481B/en unknown
- 2011-11-24 CR CR20110623A patent/CR20110623A/es unknown
- 2011-11-30 EC EC2011011493A patent/ECSP11011493A/es unknown
- 2011-12-01 DO DO2011000371A patent/DOP2011000371A/es unknown
- 2011-12-01 GT GT201100308A patent/GT201100308A/es unknown
- 2011-12-02 CU CU2011000225A patent/CU20110225A7/es unknown
- 2011-12-05 CL CL2011003085A patent/CL2011003085A1/es unknown
- 2011-12-05 IL IL216772A patent/IL216772A0/en unknown
- 2011-12-05 HN HN2011003195A patent/HN2011003195A/es unknown
- 2011-12-15 CO CO11173248A patent/CO6470897A2/es active IP Right Grant
-
2012
- 2012-02-16 TN TNP2012000073A patent/TN2012000073A1/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201100308A (es) | Derivados de 1-(piperidin-4-il)-pirazol como moduladores de gpr 119 | |
CR10949A (es) | Compuestos triciclicos, composiciones y procedimientos | |
CU20130059A7 (es) | Derivados de 4-(5-ciano-pirazol-1-il)- piperidina como moduladores de gpr 119 | |
CL2015002567A1 (es) | Compuestos y sus usos para modular la hemoglobina | |
HN2012000973A (es) | INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA | |
CR20110509A (es) | Composicion farmaceutica | |
UY35427A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
CR8741A (es) | Aril y heteroaril derivados sustituidos como moduladores del metabolismo y la prevencion y el tratamiento de trastornos relacionados | |
UY35425A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
UY35426A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
DOP2011000029A (es) | Compuestos de fenantrenona, composiciones y metodos | |
UA101110C2 (en) | L-(piperidin-4-yl)-pyrazole derivatives as gpr119 modulators | |
DOP2009000191A (es) | Compuestos triciclicos y su uso como moduladores de receptor de glucocorticoides | |
CU20080116A7 (es) | 3-aminociclopentanocarboxamidas como muduladores de receptores de quimioquinas | |
TN2013000166A1 (fr) | Derives de 4-(5-cyanopyrazol-1-yl)piperidine en tant que modulateurs du gpr119 | |
DOP2009000025A (es) | Analogos de 2-fenoxipirimidinona |